Vaccines to Prevent Infections by Oncoviruses
- 13 October 2010
- journal article
- review article
- Published by Annual Reviews in Annual Review of Microbiology
- Vol. 64 (1) , 23-41
Abstract
It has been estimated that viruses are etiological agents in approximately 12% of human cancers. Most of these cancers can be attributed to infections by human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and Kaposi's sarcoma–associated herpesvirus (KSHV). Prophylactic vaccines against other pathogenic viruses have an excellent record as public health interventions in terms of safety, effectiveness, and ability to reach economically disadvantaged populations. These considerations should prompt efforts to develop and implement vaccines against oncoviruses. Safe and effective HBV and HPV vaccines, based on virus-like particles, are commercially available, and the major focus is now on vaccine delivery, especially to low-resource settings. HCV and EBV vaccines are under active development, but few clinical trials have been conducted, and none of the candidate vaccines has proven to be sufficiently effective to warrant commercialization. Efforts to develop KSHV vaccines have been more limited.Keywords
This publication has 80 references indexed in Scilit:
- Induction of Protective Immunity against Murine Gammaherpesvirus 68 Infection in the Absence of Viral LatencyJournal of Virology, 2010
- Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus VaccinesJNCI: Journal of the National Cancer Institute, 2009
- Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activityProceedings of the National Academy of Sciences, 2009
- Hepatitis B: The virus and disease #Hepatology, 2009
- Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious MononucleosisJournal of Virology, 2008
- Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenanNature Medicine, 2007
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences, 2007
- Prospects for a vaccine against the hepatitis C virusNature, 2005
- Protective Efficacy of Multiepitope Human Leukocyte Antigen???A*0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia VirusJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- PASSIVE IMMUNIZATION AGAINST HEPATITIS B: A REVIEW OF RECENT STUDIES AND COMMENT ON CURRENT ASPECTS OF CONTROLAmerican Journal of Epidemiology, 1978